The EU MDR 2026 amendments are the most consequential shift in European medical device regulation since the original EU MDR 2017/745 entered application. For global Pharma and MedTech organizations developing Software as a Medical Device (SaMD) and Digital Therapeutics (DTx), these amendments do not simply update compliance requirements; they fundamentally changed product strategy, investment priorities, and speed […]
